UKs Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Palma de Mallorca-based Sanifit, an expert for calcification disorders, has appointed Preston Klassen as its Chief Medical Officer. Klassen will also serve as President of Sanifits newly launched US subsidiary in San Diego.
Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.
Harriet Fear, CEO of not-for-profit One Nucleus, has been appointed a Member of the Order of the British Empire in the Queens Birthday 2016 Honours List. The award recognises her services to the life science sector.
After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have on the economy, research and politics. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.
UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.
UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the companys US business development and for establishing a team in the US.
TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Sciences tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.
Manchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.
Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The companys shares, listed in London, plunged to a third of its previous value.